TrialJapanese journal of clinical oncology2019

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Yuichiro Ohe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.